

Under the Paperwork Reduction Act of 1995, no persons are required to respond to this collection of information unless it displays a currently valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	09/687,864
Filing Date	10/13/2000
First Named Inventor	Jeffrey A. Ledbetter
Group Art Unit	
Examiner Name	
Attorney Docket Number	

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique classification designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

number of the patent document. ⁵ Kind or document by which the patent was granted, if known, and the date of the patent, if known, if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to the collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **3**

C mplete if Known

Application Number	09/687,864
Filing Date	10/13/2000
First Named Inventor	Jeffrey A. Ledbetter
Group Art Unit	
Examiner Name	
Attorney Docket Number	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HOWELL, A.L., ET AL., "Targeting HIV-1 to FcgammaR on human phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells." J. of Leuk. Biol. 55: 385-391 (1994).	
		ZAGHOUANI, H., ET AL., "Induction of antibodies to the human immunodeficiency virus type I by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein." PNAS 92: 631-635 (1995).	
		SYRENGELAS, A.D., ET AL., "DNA Immunization induces protective immunity against B-cell lymphoma." Nature Med. 2: 1038-1041 (1996).	
		LIU, C., ET AL., "Fcgamma RIII on Human B Cells Can Mediate Enhanced Antigen Presentation." Cell. Immunol. 167: 188-194. (1996).	
		LIU, C., ET AL., "FcgammaRI-Targeted Fusion Proteins Result in Efficient Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes." J. Clin. Invest. 98: 2001-2007. (1996).	
		GUYRE, P.M., ET AL., "Increased Potency of Fc-receptor-targeted antigens." Cancer Immunol. Immunother. 45: 146-148 (1997).	

Examiner
Signature

Date
Consider d


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED
MAR 06 2001
TECH CENTER 1600/2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/687,864
Filing Date	10/13/2000
First Named Inventor	Jeffrey A. Ledbetter
Group Art Unit	
Examiner Name	
Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BOYLE, J.S., ET AL., "Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction." <i>Nature</i> 392: 408-411 (1998).	
		GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines." <i>Res. Immunol.</i> 149: 655-660 (1998).	
		SERRE, K., ET AL., "Efficient Presentation of Multivalent Antigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." <i>J. Immunol.</i> 161: 6059-6067. (1998).	
		RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." <i>J. of Gen Virol.</i> 80: 217-223. (1999).	
		BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity." <i>Nature Biotech.</i> 17: 253-258. (1999).	

Examiner Signature	Date Consid red
-----------------------	--------------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.